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With science and technology high on the agenda of the new US administration, scientists should 
welcome the opportunity to influence policy. However, few academic scientists seem to be noticing 
proposals posted for public comment on the Federal Register that concern the application of 
science to society.President Obama has pledged to pay 
attention to scientists, but do they know 
how to be heard? One simple way for 
scientists to contribute beyond university 
walls is to comment on proposed rules 
and guidelines within their area of exper-
tise—be it the application of genomics to 
genetic tests or recombinant technology 
to genetically modified organisms (see 
Table 1; Box 1). Once federal agencies 
have listened to public opinion, they final-
ize rules and use them to clarify laws. For 
example, the National Institutes of Health 
(NIH) is currently requesting comments, 
before May 26, on draft guidelines that 
specify which embryonic stem cell lines 
will be eligible for federal funds. Once 
finalized, these guidelines will be used 
to evaluate research proposals to ensure 
that “NIH-funded research in this area is 
ethically responsible, scientifically wor-
thy, and conducted in accordance with 
applicable law.”
The process of posting a comment 
is straightforward. During the comment 
period—which typically lasts 30, 60, or 90 
days—the public can go online (http://www.
regulations.gov), access rules and guide-
lines as they are being drafted, and submit 
a comment before the rules are finalized. 
Once the period ends, a public meeting 
on the topic is often held. Federal agency 
officials then consider each written and oral 
comment and respond; their response is 
publicly available as well.
Public participation in the process 
that makes, applies, and amends US 
federal rules has been officially encour-
aged since 1946. In 2003, it went online. 
And by the end of this year, its accessi-
bility will be enhanced due to President 
Obama’s mandate to make the rule-
making process more transparent and 
democratic. Yet despite federal encour-
agement and the ease of posting a com-
ment, scientists do not seem to be par-
ticipating unless the proposals directly impact their research. “People whose 
research is affected probably look more 
carefully” at the Federal Register, says 
Harvard geneticist Daniel Hartl. “But 
people who are more peripherally asso-
ciated tend to think that someone else 
should deal with it.”
However, the result of translating sci-
entific advances into products used by 
the general public—be it genetically engi-
neered organisms, genetic tests, stem 
cell therapy, or gene therapy—will affect 
all researchers in the long run. When con-
cerns arise about the safety of a particular 
method or product, society tends to ques-
tion science in general. “The public must 
be able to trust the science and the scien-
tific process informing public policy deci-
sions,” wrote President Obama in a mem-
orandum on scientific integrity, published 
on March 9. In response to his memo, the 
Office of Science and Technology Policy 
posted a notice on the Federal Register 
asking for recommendations from the 
public before May 13 on how to ensure 
that the scientific information that agen-
cies rely on is reliable.
Is Silence Golden?
Will scientists comment on the restric-
tions listed in the NIH’s draft guidelines 
for federal funding of stem cell research? 
“I will comment however I can,” says 
Irving Weissman, the director of the 
Stem Cell Biology and Regenerative 
Medicine Institute at Stanford Univer-
sity in Palo Alto, CA. “When you read 
the guidelines, the NIH says it will not 
use stem cells derived by [somatic cell] 
nuclear transfer,” he says. “I hope they 
use this time of comments to rethink the 
issue of why they want to ban funding, 
especially when it might be the sole way 
to treat real human disease.”
George Daley, the director of the stem 
cell transplantation program at Chil-
dren’s Hospital in Boston, has concerns Cell about the eligibility of existing embryonic 
stem cell lines established from embryos 
whose donors chose to discard them but 
might not have been informed of alterna-
tive options required for consent today. 
“It’s problematic to hold yesterday’s cell 
lines to today’s informed consent stan-
dards,” Daley says. “Lines derived long 
ago by the highest standards of the time 
and with thoughtful informed consent 
should be ‘grandfathered’ into the new 
policy.”
Another notice up for comment until 
May 15 poses questions about whether 
certain gene patenting and licensing 
practices may have adverse effects on 
the cost and quality of genetic tests and 
on patients’ access to them. In part, this 
notice is a response to recent controver-
sies about restrictive patents on disease 
genes such as the BRCA1 and BRCA2 
genes associated with breast and ovar-
ian cancer. Critics have argued that the 
Box 1. Glossary
Regulations.gov: A website (http://www.
regulations.gov) on which users can access 
all Federal Register documents open for 
comment across the Federal government. 
In addition, the public can find, view, and 
comment on additional rulemaking and 
non-rulemaking documents.
Federal Register: The official daily publica-
tion for rules, proposed rules, and notices of 
Federal agencies and organizations, as well 
as executive orders and other presidential 
documents.
Rulemaking: The process followed by 
Federal departments and agencies to for-
mulate, amend, or repeal a regulation.
Docket: A repository for all materials spe-
cifically referenced in the Federal Register 
document, any public comments received, 
and other information used by decision-
makers or otherwise related to rulemaking 
activity, such as supporting analyses. 
Comment: A written expression of an opin-
ion or attitude by a member of the public to 
a government agency about a rulemaking or 
other action.
Source: Regulations.gov137, May 15, 2009 ©2009 Elsevier Inc. 595
Table 1. Federal Register Documents for Public Comment
Document ID Dated Agency Explanation Comments due by
Selected Documents Open for Comment as of April 30, 2009
FR Doc. E9-5936 March 19, 2009 National Institutes of Health (NIH) Request for public comment 
on “Public Consultation Draft 
Report on Gene Patents and 
Licensing Practices and Their 
Impacts on Patient Access to 
Genetic Tests”
May 15, 2009
FR Doc. E9-8352 April 7, 2009 Animal, Plant and Health 
 Inspection Service, USDA
Proposed rule revising r egulations 
on “Importation, Interstate 
 Movement, and Release Into the 
Environment of Certain  Genetically 
Engineered Organisms”
June 29, 2009
FR Doc E9-9313 April 17, 2009 NIH Notice and request for public 
comment on draft guidelines 
“National Institutes of Health 
Guidelines for Human Stem Cell 
Research”
May 26, 2009
FR Doc. E9-9307 April 23, 2009 Office of Science and  
Technology Policy
Request for public comment on 
the Presidential Memorandum 
on Scientific Integrity
May 13, 2009
FR Doc. E9-9131 April 14, 2009 NIH Meeting notice and request 
for comments that will be 
 discussed at the meeting,  
“New Dimensions and Strate-
gies for Women’s Health 
Research for the NIH”  
May 15, 2009
FR Doc. E9-7350 March 27, 2009 FDA Notice and request for 
 comments on “Draft  Guidance 
for Industry: Somatic Cell 
Therapy for Cardiac Disease”
July 1, 2009
FR Doc. E9-4618 February 26, 2009 NIH Notice of proposed changes to 
“NIH Guidelines for Research 
with Recombinant DNA” that 
expands the scope to cover 
research with synthetic nucleic 
acid molecules
May 4, 2009
Documents Referenced but No Longer Open for Comment
FR Doc. E8-29114 December 2, 2008 EPA Meeting notice and request 
for comments that will be 
 discussed at the meeting to 
review issues pertaining to 
the resistance risks of using a 
 transgenic seed mix
February 9, 2009
FR Doc. E9-4100 February 23, 2009 National Science Foundation  
(NSF)
Request for public comment 
on a requirement for students 
and postdoctoral researchers 
involved in NSF proposals to be 
educated in the responsible and 
ethical conduct of research
March 31, 2009
FR Doc. E8-21917 September 15, 2008 FDA Notice and request for public 
comment on draft  guidance 
for industry “Regulation 
of  Genetically Engineered 
Animals Containing Heritable 
 Recombinant DNA Constructs”
November 18, 2008 
FDA-2008-D-0394-0274 January 15, 2009 FDA Final Guidance for Industry 
“Regulation of Genetically 
Engineered Animals Containing 
Heritable Recombinant DNA 
Constructs”
Comment period has 
closed. Contact the 
FDA staff listed on the 
guidance to discuss an 
alternative approach.
Source: The Federal Register (http://www.gpoaccess.gov) and Regulations.gov.596 Cell 137, May 15, 2009 ©2009 Elsevier Inc.
monopoly held by biotech companies on 
patented genes keeps the cost of diag-
nostic tests high and also limits the abil-
ity of other groups to analyze the genes 
and improve the reliability of tests.
Scientists can choose to be alerted by 
email as rules on stem cells, recombinant 
molecules, and other topics of interest 
appear on the Federal Register by sign-
ing up at http://www.regulations.gov. 
Newsletters sent from nongovernmen-
tal science societies sometimes include 
notifications when pertinent rulings are 
open for public comment. For example, in 
March this year, the Federation of Ameri-
can Societies for Experimental Biology 
(FASEB) let their members know about 
a proposal from the National Science 
Foundation (NSF) that would require NSF 
grantees to teach students and postdocs 
about the ethics of research. FASEB 
responded with a comment on behalf of 
their members, asking that online training 
be acceptable. Meanwhile, the Union of 
Concerned Scientists is encouraging its 
members to submit comments on the first 
comprehensive revision since 1987 of reg-
ulations regarding the release and impor-
tation of genetically engineered plants 
and invertebrates. The comment period 
on this important proposal has been 
extended until June 29. And the Interna-
tional Society for Stem Cell Research has 
circulated emails asking their members to 
prepare comments in response to the NIH 
stem cell guidelines so that they can sub-
mit a comment on behalf of the society.
Calling All Scientists
People affiliated with biotechnology com-
panies and advocacy groups often flood 
the Federal Register with comments. For 
example, draft guidelines posted by the 
US Food and Drug Administration (FDA) 
regarding genetically engineered animals 
that produce drugs, vitamins, or other 
marketable traits received some 200 com-
ments earlier this year; only a few were 
from scientists at academic institutions.
“It may be that the academic commu-
nity is not familiar with the commenting 
process and did not understand that they 
could comment,” says Larisa Rudenko, 
senior advisor for biotechnology at the FDA and the agency’s point person for 
animal biotechnology. “We were hoping 
more academics would comment on the 
guidance” because their comments tend 
to be substantial and specific, she says.
Rules usually take years to finalize, 
in part because federal agencies do 
not want to downplay risks. Documents 
posted on the Federal Register often 
direct questions to scientists, soliciting 
advice on say, the mutability of certain 
gene constructs. Although the first FDA 
approved biopharm animals—goats 
producing anticoagulant drugs—were 
approved soon after the guidance was 
finalized, the FDA staff responsible for 
implementing the guidance can still 
be reached. “After every point [in the 
process], come in, comment, or call,” 
Rudenko says. “You don’t need to sub-
mit a package, just give us a call and 
we’ll work with you.” Rudenko says the 
last thing the FDA wants to do is frighten 
off academics by presenting themselves 
as bureaucratic or unresponsive.
Yet when asked what he knows about 
the Federal Register, Kristofor Langlais, 
a molecular geneticist at the NIH in 
Bethesda, MD, answers, “I don’t know 
exactly what it is, but I’ve heard of it.” 
He says that although he cannot speak 
for others, he can guess why scientists 
rarely get involved with policy. “Most 
science programs teach science…but 
neglect to include training in how sci-
ence and society go together,” he says. 
“My hunch is that scientists that never 
had a significant society aspect included 
in their training don’t feel comfort-
able getting involved with these issues, 
because perhaps the mechanisms by 
which policy is developed and adapted 
are so foreign.”
“In all fairness, scientists working 
day to day are not going to read the 
Register unless someone prods them 
to comment,” says Neil Holtzman, now 
a professor emeritus at Johns Hopkins 
School of Medicine and author of the 
1989 book Proceed with Caution: Pre-
dicting Genetic Risks in the Recombi-
nant DNA Era. But it is not a time issue, 
he says. Perhaps the issue is where their 
concerns lie. When the various scientific Cellsocieties he belonged to sent him emails 
or letters asking that he comment on a 
federal proposal, he says these requests 
rarely involved public policy. “I got letters 
asking about expanding the budget [for 
research], but I seldom got a letter say-
ing here’s a policy that’s harmful to the 
public, would you write a letter?”
Instead, Holtzman and a handful of 
other scientists influenced public policy 
on their own, by expressing their con-
cerns about the Human Genome Project 
as it emerged in the early 1990s. Later, 
when Holtzman co-chaired the NIH-
DOE Task Force on Genetic Testing, he 
helped to persuade the US Department 
of Health and Human Services to create 
a committee on genetic testing.
Read Regs, Run Gel, Post Comment
Posting a comment may be less effec-
tive than testifying before Congress or 
serving on a federal task force like Holtz-
man did, but it is a way to strengthen 
the voice of science without impact-
ing research productivity or teaching 
responsibilities. It took very little time 
for Bruce Tabashnik, an entomologist 
at the University of Arizona in Tucson, 
to compose his comment for the Reg-
ister. “Were my two hours worth it?” he 
says, “Absolutely.” Jeannette Martinez 
of the Environmental Protection Agency 
(EPA) had met Tabashnik at an ento-
mology meeting and later asked him to 
post a comment on a model of insect 
resistance to an insecticide produced 
by transgenic corn. In his comment, 
Tabashnik enumerated reasons why 
he thought that the assumptions of the 
model, submitted by the company that 
produced the corn, were incorrect. The 
final decision has yet to be released, but 
Tabashnik says he is satisfied knowing 
that his letter triggered a debate over 
something that would have otherwise 
been regarded as fact.
Commenting does not pay and may 
not improve a CV, but according to 
Tabashnik, there are emotional benefits. 
He says, “I invest my life in developing 
knowledge in one area and I see it as 
rewarding to even expend the effort to 
have it be of some use to society.”
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